RIFAXIMIN and DEATH

Overview

DEATH is the #1 most commonly reported adverse reaction for RIFAXIMIN, manufactured by Salix Pharmaceuticals, Inc.. There are 3,983 FDA adverse event reports linking RIFAXIMIN to DEATH. This represents approximately 10.7% of all 37,072 adverse event reports for this drug.

Patients taking RIFAXIMIN who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

DEATH is a frequently reported adverse event for RIFAXIMIN, accounting for a significant proportion of all reports.

Other Side Effects of RIFAXIMIN

In addition to death, the following adverse reactions have been reported for RIFAXIMIN:

• HOSPITALISATION — 1,704 reports
• DIARRHOEA — 1,193 reports
• OFF LABEL USE — 1,133 reports
• THERAPY INTERRUPTED — 989 reports
• AMMONIA INCREASED — 831 reports
• NAUSEA — 802 reports
• FATIGUE — 779 reports
• HEPATIC ENCEPHALOPATHY — 762 reports
• DRUG INEFFECTIVE — 713 reports
• CONFUSIONAL STATE — 711 reports

Other Drugs Associated with DEATH

The following drugs have also been linked to death in FDA adverse event reports:

Does RIFAXIMIN cause DEATH?

DEATH has been reported as an adverse event in 3,983 FDA reports for RIFAXIMIN. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is DEATH with RIFAXIMIN?

DEATH accounts for approximately 10.7% of all adverse event reports for RIFAXIMIN, making it one of the most commonly reported side effect.

What should I do if I experience DEATH while taking RIFAXIMIN?

If you experience death while taking RIFAXIMIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages